IL-2 gene transfer in immunotherapy of cancer: local administration of IL-2-activated lymphocytes and X63-m-IL-2 cells constitutively producing IL-2 inhibits growth of plasmacytomas in syngeneic mice
Jazyk angličtina Země Švýcarsko Médium print
Typ dokumentu časopisecké články, práce podpořená grantem, Research Support, U.S. Gov't, P.H.S.
Grantová podpora
CA 39632
NCI NIH HHS - United States
PubMed
1758466
Knihovny.cz E-zdroje
- MeSH
- aktivace lymfocytů MeSH
- buňky K aktivované lymfokiny imunologie MeSH
- cytotoxicita imunologická MeSH
- imunoterapie adoptivní * MeSH
- interleukin-2 biosyntéza genetika terapeutické užití MeSH
- myši inbrední BALB C MeSH
- myši MeSH
- nádorové buňky kultivované MeSH
- plazmocytom terapie MeSH
- transfekce MeSH
- transformované buněčné linie imunologie MeSH
- transplantace izogenní MeSH
- transplantace nádorů MeSH
- tumor infiltrující lymfocyty imunologie MeSH
- zvířata MeSH
- Check Tag
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Research Support, U.S. Gov't, P.H.S. MeSH
- Názvy látek
- interleukin-2 MeSH
Peritumoral administration of X63-m-IL-2 cells, transformed by IL-2 cDNA and constitutively producing large quantities of IL-2, was effective in mediating regression of X63-Ag8.653 plasmacytomas transplanted in syngeneic mice. Injection of killer cells with LAK activity substantially enhanced the tumor-inhibitory effect of IL-2-producing cells. In vitro activation of murine bone marrow and spleen cells with IL-2 produced by the X63-m-IL-2 cell line resulted in generation of lymphocytes with oncolytic activity against X63-Ag8.653 plasmacytomas and a variety of other target cell lines. The cytolytic activity of adherent IL-2-activated killer cells (A-LAK) was substantially higher than that of a nonadherent subset. Bone marrow and spleen cells from both healthy control and tumor-bearing mice contained LAK precursors, but the cytolytic activity derived from tumor-bearing mice was lower than that from healthy controls.
